annual EBITDA:
-$276.74M-$64.75M(-30.54%)Summary
- As of today (September 7, 2025), XENE annual EBITDA is -$276.74 million, with the most recent change of -$64.75 million (-30.54%) on December 31, 2024.
- During the last 3 years, XENE annual EBITDA has fallen by -$198.65 million (-254.40%).
- XENE annual EBITDA is now -2261.85% below its all-time high of $12.80 million, reached on December 31, 2013.
Performance
XENE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$93.60M-$21.52M(-29.85%)Summary
- As of today (September 7, 2025), XENE quarterly EBITDA is -$93.60 million, with the most recent change of -$21.52 million (-29.85%) on June 1, 2025.
- Over the past year, XENE quarterly EBITDA has dropped by -$25.13 million (-36.71%).
- XENE quarterly EBITDA is now -1158.16% below its all-time high of $8.85 million, reached on September 30, 2014.
Performance
XENE quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$315.53M-$25.13M(-8.66%)Summary
- As of today (September 7, 2025), XENE TTM EBITDA is -$315.53 million, with the most recent change of -$25.13 million (-8.66%) on June 1, 2025.
- Over the past year, XENE TTM EBITDA has dropped by -$81.81 million (-35.01%).
- XENE TTM EBITDA is now -2306.28% below its all-time high of $14.30 million, reached on September 30, 2014.
Performance
XENE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XENE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.5% | -36.7% | -35.0% |
| 3 y3 years | -254.4% | -212.6% | -263.1% |
| 5 y5 years | -596.1% | -10000.0% | -999.1% |
XENE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -254.4% | at low | -212.6% | at low | -263.1% | at low |
| 5 y | 5-year | -889.5% | at low | <-9999.0% | at low | -999.1% | at low |
| alltime | all time | -2261.8% | at low | -1158.2% | at low | -2306.3% | at low |
XENE EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$93.60M(+29.9%) | -$315.53M(+8.7%) |
| Mar 2025 | - | -$72.08M(-6.2%) | -$290.39M(+4.9%) |
| Dec 2024 | -$276.74M(+30.5%) | -$76.84M(+5.3%) | -$276.77M(+9.5%) |
| Sep 2024 | - | -$73.01M(+6.6%) | -$252.77M(+8.2%) |
| Jun 2024 | - | -$68.46M(+17.1%) | -$233.71M(+6.1%) |
| Mar 2024 | - | -$58.45M(+10.6%) | -$220.27M(+4.6%) |
| Dec 2023 | -$211.99M(+66.0%) | -$52.84M(-2.1%) | -$210.51M(+5.0%) |
| Sep 2023 | - | -$53.95M(-1.9%) | -$200.49M(+8.8%) |
| Jun 2023 | - | -$55.02M(+13.0%) | -$184.31M(+15.8%) |
| Mar 2023 | - | -$48.70M(+13.7%) | -$159.22M(+24.9%) |
| Dec 2022 | -$127.74M(+63.6%) | -$42.82M(+13.4%) | -$127.52M(+16.7%) |
| Sep 2022 | - | -$37.77M(+26.2%) | -$109.27M(+25.8%) |
| Jun 2022 | - | -$29.94M(+76.2%) | -$86.89M(+9.7%) |
| Mar 2022 | - | -$16.99M(-30.8%) | -$79.22M(+1.4%) |
| Dec 2021 | -$78.09M(+179.2%) | -$24.57M(+59.6%) | -$78.09M(+17.9%) |
| Sep 2021 | - | -$15.39M(-30.9%) | -$66.24M(+9.7%) |
| Jun 2021 | - | -$22.27M(+40.4%) | -$60.38M(+56.5%) |
| Mar 2021 | - | -$15.86M(+24.7%) | -$38.59M(+25.9%) |
| Dec 2020 | -$27.97M(-29.7%) | -$12.72M(+33.5%) | -$30.66M(+4.3%) |
| Sep 2020 | - | -$9.53M(+1889.1%) | -$29.39M(+2.4%) |
| Jun 2020 | - | -$479.00K(-94.0%) | -$28.71M(-25.7%) |
| Mar 2020 | - | -$7.93M(-30.8%) | -$38.64M(-8.8%) |
| Dec 2019 | -$39.76M | -$11.45M(+29.4%) | -$42.39M(+8.1%) |
| Sep 2019 | - | -$8.85M(-15.0%) | -$39.23M(+2.1%) |
| Jun 2019 | - | -$10.41M(-10.8%) | -$38.42M(+8.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$11.68M(+40.8%) | -$35.44M(+12.8%) |
| Dec 2018 | -$32.54M(+8.3%) | -$8.29M(+3.2%) | -$31.42M(+1.3%) |
| Sep 2018 | - | -$8.04M(+8.1%) | -$31.03M(-1.4%) |
| Jun 2018 | - | -$7.43M(-2.9%) | -$31.47M(-0.9%) |
| Mar 2018 | - | -$7.66M(-3.1%) | -$31.76M(-0.5%) |
| Dec 2017 | -$30.05M(+25.5%) | -$7.90M(-6.7%) | -$31.93M(+8.9%) |
| Sep 2017 | - | -$8.48M(+9.7%) | -$29.32M(+4.7%) |
| Jun 2017 | - | -$7.72M(-1.3%) | -$28.01M(+6.1%) |
| Mar 2017 | - | -$7.82M(+47.7%) | -$26.40M(+10.2%) |
| Dec 2016 | -$23.95M(+187.8%) | -$5.30M(-26.1%) | -$23.95M(+14.2%) |
| Sep 2016 | - | -$7.16M(+17.1%) | -$20.98M(+46.0%) |
| Jun 2016 | - | -$6.12M(+13.8%) | -$14.37M(+85.0%) |
| Mar 2016 | - | -$5.38M(+131.8%) | -$7.77M(+129.0%) |
| Dec 2015 | -$8.32M(-170.3%) | -$2.32M(+315.6%) | -$3.39M(+307.2%) |
| Sep 2015 | - | -$558.00K(-215.3%) | -$833.00K(-109.7%) |
| Jun 2015 | - | $484.00K(-148.4%) | $8.57M(-11.1%) |
| Mar 2015 | - | -$999.00K(-516.3%) | $9.64M(-18.6%) |
| Dec 2014 | $11.84M(-7.5%) | $240.00K(-97.3%) | $11.85M(-17.2%) |
| Sep 2014 | - | $8.85M(+469.6%) | $14.30M(+19.1%) |
| Jun 2014 | - | $1.55M(+28.7%) | $12.01M(+14.9%) |
| Mar 2014 | - | $1.21M(-55.2%) | $10.46M(+13.1%) |
| Dec 2013 | $12.80M(-474.1%) | $2.70M(-58.9%) | $9.25M(+41.1%) |
| Sep 2013 | - | $6.55M | $6.55M |
| Dec 2012 | -$3.42M(-68.2%) | - | - |
| Dec 2011 | -$10.77M | - | - |
FAQ
- What is Xenon Pharmaceuticals Inc. annual EBITDA?
- What is the all time high annual EBITDA for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. annual EBITDA year-on-year change?
- What is Xenon Pharmaceuticals Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. quarterly EBITDA year-on-year change?
- What is Xenon Pharmaceuticals Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. TTM EBITDA year-on-year change?
What is Xenon Pharmaceuticals Inc. annual EBITDA?
The current annual EBITDA of XENE is -$276.74M
What is the all time high annual EBITDA for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high annual EBITDA is $12.80M
What is Xenon Pharmaceuticals Inc. annual EBITDA year-on-year change?
Over the past year, XENE annual EBITDA has changed by -$64.75M (-30.54%)
What is Xenon Pharmaceuticals Inc. quarterly EBITDA?
The current quarterly EBITDA of XENE is -$93.60M
What is the all time high quarterly EBITDA for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high quarterly EBITDA is $8.85M
What is Xenon Pharmaceuticals Inc. quarterly EBITDA year-on-year change?
Over the past year, XENE quarterly EBITDA has changed by -$25.13M (-36.71%)
What is Xenon Pharmaceuticals Inc. TTM EBITDA?
The current TTM EBITDA of XENE is -$315.53M
What is the all time high TTM EBITDA for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high TTM EBITDA is $14.30M
What is Xenon Pharmaceuticals Inc. TTM EBITDA year-on-year change?
Over the past year, XENE TTM EBITDA has changed by -$81.81M (-35.01%)